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DOI 10.1016/j.ccr.2011.03.009SUMMARYPhysiological levels of KrasG12D are sufficient to induce pancreatic intraepithelial neoplasias (PanINs); the
mechanisms that drive PanIN progression are unknown. Here, we establish that, in addition to oncogenic
KrasG12D, IL-6 transsignaling-dependent activation of Stat3/Socs3 is required to promote PanIN progression
and pancreatic ductal adenocarcinoma (PDAC). Myeloid compartment induces Stat3 activation by secreting
IL-6; consequently, IL-6 transsignaling activates Stat3 in the pancreas. Using genetic tools, we show that
inactivation of IL-6 transsignaling or Stat3 inhibits PanIN progression and reduces the development of
PDAC. Aberrant activation of Stat3 through homozygous deletion ofSocs3 in the pancreas accelerates PanIN
progression and PDAC development. Our data describe the involvement of IL-6 transsignaling/Stat3/Socs3
in PanIN progression and PDAC development.INTRODUCTION
Despite the considerable efforts that have been made in basic
and clinical research, pancreatic ductal adenocarcinoma
(PDAC) affects 230,000 patients in the Western Hemisphere
annually. PDAC is notable for its high mortality, constituting the
fourth leading cause of death due to cancer (Hidalgo, 2010).
Recent efforts have helped identify the molecular genetic
determinants of PDAC. Activating KRAS mutations have been
detected in 30%ofpancreatic intraepithelial neoplasias (PanINs),
which are precursor lesions, increasing to 100% in advanced
PDACs. Inactivation of INK4A and TRP53 occurs later during
PanIN progression and PDAC formation (Hruban et al., 2006).
These findings have been mirrored in mouse models.
Pancreas-specific expression of mutations (KrasG12D, KrasG12V,
KrasG12D, Trp53R172H) or deletion of tumor suppressor genesSignificance
Despite the availability of current multimodal therapies, treatm
are poor, generating overall survival rates of less than 5%. L
therapy contribute to this dismal prognosis. Although genetic
the initial, frequently occurring genetic alterations, signalin
described. In this study, we implicate the IL-6 transsignaling
progression and PDAC development.
456 Cancer Cell 19, 456–469, April 12, 2011 ª2011 Elsevier Inc.(Trp53, Ink4A/Arf) in genetically engineered mice (GEM) recapit-
ulates PanIN initiation and progression to pancreatic cancer
(PC), similar to the clinical pathology (Aguirre et al., 2003; Guerra
et al., 2007; Hingorani et al., 2003, 2005; Kelly et al., 2008).
Although it has been studied in GEM for pancreatic cancer, the
role of concomitant stromal reactions (stromal desmoplasia) in
PanIN progression and cancer development has not been
addressed; most existing concepts have merely been inferred.
The presence of stromal desmoplasia is a hallmark of PDAC
(Algul et al., 2007b), forming a unique microenvironment that
comprises many cell types, including proliferating fibroblasts
and pancreatic stellate cells that produce and deposit fibro-
nectin and collagen, and inflammatory cells and macrophages
that release chemokines and cytokines. In particular, the func-
tion of concomitant inflammation in PDAC has garnered recent
interest, because proinflammatory markers in the serum, suchent outcomes in pancreatic ductal adenocarcinoma (PDAC)
ate diagnosis, early metastasis, and the lack of a specific
studies have observed that activating Kras mutations are
g pathways that drive PanIN progression have not been
/Stat3/Socs3 pathway as an important mediator of PanIN
PDAC
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Figure 1. Non-Cell-Autonomous Activation of Stat3Y705 in
Pancreatic Cancer
(A) Western blot analysis of p-Stat3Y705 in normal pancreas (LSL-KrasG12D) and
18 week old noncancer-bearing KrasG12D (non-PDAC) and cancer-bearing
KrasG12D (PDAC) (ID 9907, 16069, 17027) mice.
(B–D) Immunohistochemical analysis of p-Stat3Y705 in LSL-KrasG12D pancreas
(B), pancreatic cancer (C), and liver metastases (D) from KrasG12D mice
(representative PDAC, ID 14128). Black arrows indicate p-Stat3Y705 in infil-
trating cells (C); white arrows indicate hepatocytes (D). Black stars indicate
malignant cells.
(E) Various cell lines from primary tumors and metastases were examined for
constitutive phosphorylation of Stat3. b-actin served as the control. Scale bars
equal 50 mM.
See also Table S1.
Cancer Cell
IL-6 Transsignaling and Stat3 in Pancreatic Canceras interleukin (IL)-1b and IL-6, are associated with outcomes in
PDAC (Ebrahimi et al., 2004; Sawai et al., 2003). Additionally,
chronic pancreatitis is a risk factor for PDAC, supporting the
involvement of concomitant inflammation in pancreatic onco-
genesis (Lowenfels et al., 1993).
Dysregulated activation of signal transducer and activator of
transcription (Stat) family members occurs often in many human
malignancies. Of the seven Stat proteins, activation of Stat3 in
cancer is related to tumor growth directly through tumor-auton-
omous mechanisms and indirectly by modulating tumor-associ-
ated stroma and the immune system. Activation depends on the
phosphorylation of a conserved tyrosine residue (Y705) by
upstream kinases, such as Janus kinase 2 (Jak2). Jak2 activation
requires activation of the ubiquitously expressed gp130 receptor
by specific ligands (IL-6, leukemia inhibitor factor [LIF], IL-11,
oncostatin M [OSM], ciliary neurotrophic factor [CNTF], IL-27).
Of these ligands, IL-6 has the unique capacity to activate Stat3
using twomodes. The firstmode entails classical signalingmech-
anisms, characterized by the binding of IL-6 to the IL-6 receptor
(IL-6R) andgp130onspecific target cells.However, a fewsubsets
of cells, such as monocytes/macrophages and hepatocytes,
express the membrane-bound IL-6R, whereas gp130 is ubiqui-
tously expressed. Alternatively, IL-6 binds to a naturally occurring
soluble form of IL-6R (sIL-6R), forming a complex that induces
IL-6-specific signaling in cells that lack membrane-bound IL-6R,
a process that is called IL-6 transsignaling. In humans, sIL-6R is
generated either by alternative splicing or by proteolytic release
of the ectodomain of the membrane-bound IL-6R, whereas in
the mouse, sIL-6R is exclusively generated by proteolysis
(Rose-John and Heinrich, 1994). All of these events result in the
dimerization of phosphorylated Stat3 monomers via Src
homology-2 (SH2) domains, shifting them into a transcriptionally
active conformation. Stat3 regulates its own endogenous inhib-
itor, Socs3, to form a negative feedback loop (Yu et al., 2009).
Stat3 activation in PDAC has been documented in human
tissues and pancreatic cancer cell lines, although the mecha-
nism of Stat3 activation in the absence of JAK2 mutations and
its function in pancreatic oncogenesis has not been examined
(Kocher et al., 2007; Scholz et al., 2003).
In the present study, we aim to identify the role of the IL-6
dependent Stat3 signaling pathway in pancreatic cancer using
genetically engineered mouse models.
RESULTS
Non-Cell-Autonomous Activation of Stat3Y705
in Pancreatic Cancer
Although Stat3 activation occurs in human PanIN, PC, and
pancreatic cancer cell lines, its function in pancreatic carcino-
genesis has not been examined (Scholz et al., 2003). First, we
determined whether this finding could be repeated in KrasG12D
mice. KrasG12D mouse lines express a constitutively active
form of mutated K-Ras in the pancreas, thereby recapitulating
the entire spectrum of pancreatic carcinogenesis that is
observed in humans (Hingorani et al., 2003).
Phosphorylation of Stat3Y705 was analyzed in four PDACs (ID
14128, 9907, 17027, 16069) (see Table S1 available online)
derived from KrasG12D mice by immunohistochemistry (IHC)
and immunoblot (IB). By IB, p-Stat3Y705 levels were highest inPDAC (ID 9907, 16069, 17027) compared with 18 week old non-
tumor KrasG12D mice, which harbor numerous low-grade PanIN
lesions. Normal pancreas (LSL-KrasG12D) was negative for
p-Stat3Y705 (Figure 1A).Cancer Cell 19, 456–469, April 12, 2011 ª2011 Elsevier Inc. 457
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Figure 2. Myeloid Cells are the Cellular Source of IL-6
(A) Relative expression of IL-6 mRNA in whole pancreas in 9, 13, and 18 week old KrasG12D mice. Data are expressed as fold increase compared with controls
(LSL- KrasG12D mice). Means ± SD (nR 5). *p < 0.05. **p <0 .005.
(B) IL-6-dependent activation of p-Stat3Y705 in one representative PDAC cell line (ID 14128).
(C and D) Immunohistochemical localization of F/80 and IL-6 in the pancreas of 9 week old KrasG12D mice. White arrows indicate infiltrating cells; black star
indicates acini.
(E–J) Immunohistochemical staining of F4/80 and CD3 in the pancreas of 9, 13, and 18 week old KrasG12D mice.
(K) Pancreata from three mice were pooled and analyzed for macrophages (CD45+ F4/80+CD11b+CD11c), dendritic cell (CD45+CD11c+CD11b+F4/80), T cell
(CD45+CD3+), and B cell (CD45+CD19+) content by fluorescence-activated cell sorting (FACS). The percentages of these cells were determined and normalized
to 9 week old mice. Means ± SD (n = 3), *p < 0.05.
(L) Percentages of macrophages (CD45+F4/80+CD11b+CD11c) in the pancreas during acute pancreatitis. Acute pancreatitis was induced by repetitive hourly
injections of cerulein. Pancreata from three C57BL/6 mice were pooled and analyzed by FACS. Means ± SD (n = 3), **p < 0.005. Scale bars equal 50 mM.
See also Figure S1.
Cancer Cell
IL-6 Transsignaling and Stat3 in Pancreatic CancerBy IHC of PDAC (ID 14128) in KrasG12D mice, we observed
strong phosphorylation of Stat3 at tyrosine residue 705 in
primary cancers (Figure 1C) and their metastases (Figure 1D) in
contrast to normal pancreas (LSL-KrasG12D) (Figure 1B), similar
to findings in humans. Notably, p-Stat3Y705 was restricted to
malignant cells (Figure 1B, black stars) and infiltrating cells (Fig-
ure 1B, black arrows) or hepatocytes (Figure 1B, white arrows)
that surrounded the metastasis. These data suggest that the
level of Stat3 activation correlates with the progression of
PanINs to PDAC. Moreover, Stat3Y705 phosphorylation is
restricted to malignant cells and cells in the microenvironment.
To examine the mechanism of Stat3 activation in vitro, we
generated cell lines from primary (pancreas) and metastatic
(liver, lung, ascites) tumors (ID 9907, 16069, 17027; see Table
S1). In contrast to their primary tumors or metastases, the iso-
lated cancer cell lines showed low-level Stat3 activation in vitro
or none at all (Figure 1E; for ID numbers, see Table S1). This
observation is consistent with non-cell-autonomous phosphory-458 Cancer Cell 19, 456–469, April 12, 2011 ª2011 Elsevier Inc.lation of Stat3. Likely, Stat3 phosphorylation depends on the
microenvironment of the PDAC.
To determine the mechanisms and factors through which
Stat3 is phosphorylated in vivo, we measured the expression
of gp130 ligands (IL-6, LIF, OSM, CNTF, IL-11) in the pancreas
of KrasG12D mice, because these ligands activate the Stat3
cascade. Only IL-6 mRNA levels increased robustly and time
dependently (Figure 2A); the levels of LIF, OSM, CNTF, and
IL-11 remained unchanged or rose slightly (Figure S1A). The
primary cancer cell lines that were derived from KrasG12D mice
(ID 14128) responded to IL-6, experiencing strong phosphoryla-
tion of Stat3 (Figure 2B).
Due to its high expression in nontumor KrasG12D mice and its
abilty to activate the Stat3 cascade in PDAC cell lines, we deter-
mined the cellular source of IL-6. By IHC, IL-6 was expressed
predominantly by infiltrating immune cells (Figure 2C, white
arrow); acinar cells expressed low levels (Figure 2C, black
star). These pancreatic infiltrates in KrasG12D mice comprised
Cancer Cell
IL-6 Transsignaling and Stat3 in Pancreatic Cancerprimarily F4/80-positive macrophages (Figures 2D and 2E–2G)
and rare CD3-positive (Figures 2H–2J) cells. The inflammatory
response in KrasG12D mice was accompanied by the elevated
expression of MCP-1, MIP-2, KC, MIP-1a, IL-1b, and ICAM-1
mRNA (Figure S1B).
To characterize the cellular composition of these infiltrates, we
digested the pancreas to immunophenotype the inflammatory
cells. By flow cytometry, among CD45-positive cells in KrasG12D
mice, the fraction of F4/80+CD11b+ (macrophages, CD45+F4/
80+CD11b+CD11c) cells increased, as did CD11c+ cells
(dendritic cells, CD45+CD11c+CD11b+F4/80) to a lesser extent
(Figure 2K). However, the accumulation of F4/80+CD11b+ cells
(macrophages) was less compared with that in acute pancrea-
titis (AP) (Figure 2L). Consistent with the immunohistochemistry
findings, the cellular proportion of lymphocytes did not increase.
In summary, our data demonstrate the time-dependent
recruitment of inflammatory cells to the pancreas in KrasG12D
mice. We identified macrophages (CD45+F4/80+CD11b+
CD11c) as the chief component of the cellular infiltrate and
the source of IL-6 during pancreatic oncogenesis.
IL-6 Transsignaling Promotes PanIN Progression
Based on these findings, we hypothesized that Stat3 activation
in pancreatic oncogenesis depends on the microenvironment,
particularly on myeloid cells that secrete the gp130 ligand IL-6.
To examine the interaction between macrophages and acinar
cells that harbor KrasG12D, we developed a coculture system in
which macrophages were isolated from the pancreas of
18 week old KrasG12D mice and incubated with acinar cells
derived from KrasG12D mice. Even prestimulation of the macro-
phages with IL-6 was insufficent to induce robust Stat3 activa-
tion in KrasG12D acinar cells. These data suggest that factors
other than IL-6 are required to activate Stat3 in acinar cells
from KrasG12D mice (Figure S2A).
IL-6 signals are transmitted via gp130 through IL-6 engage-
ment of IL-6R or formation of a complex with soluble IL-6R,
that latter of which is called IL-6 transsignaling. To determine
the effects of IL-6 on the pancreas, we extended our in vitro anal-
ysis in acinar cells that were isolated from KrasG12D mice.
As shown in Figure 3A, only the IL-6R/IL-6 complex (termed as
Hyper-IL-6) induced robust phosphorylation of Stat3 in acinar
cells; IL-6 resulted only in slight phosphorylation. These data
suggest that acinar cells require IL-6 transsignaling, rather than
classical IL-6 signaling, to activate Stat3 in response to IL-6.
To characterize the impact of classical and IL-6 transsignaling
on PanIN progression in vivo, KrasG12D mice were interbred with
Il-6-/- and sgp130tg mice to obtain KrasG12D;Il-6-/- and
KrasG12D;sgp130tg mice. Transgenic sgp130tg mice postnatally
overexpress circulating sgp130Fc postnatally under control of
the hepatic PEPCK promoter, thereby specifically inhibiting IL-6
transsignaling (Rabe et al., 2008). The genetic deletion of IL-6 in
Il-6-/- mice occurs in the germ line and affects classical and IL-6
transsignaling. These strains were observed for 18 weeks.
By histology,KrasG12Dmicedeveloped numerousMUC5-posi-
tive (Figure 3D), low- and high-grade PanINs (Figures 3B and 3C,
black arrow and black star) at 18 weeks, while KrasG12D;Il-6-/-
mice had fewer and predominantly low-grade PanINs (Figures
3E–3G). Notably, postnatal inactivation of IL-6 transsignaling in
KrasG12D;sgp130tg mice had a similar effect on PanIN formation:PanIN-1 and PanIN-2 lesion numbers fell significantly in these
mice (Figures 3H–3K). Impaired PanIN progression correlated
with phosphorylated Stat3 levels in the pancreas; IHC and IB
analysis demonstrated less phosphorylated Stat3 on tyrosine
705 in KrasG12D;Il-6-/- and KrasG12D;sgp130tg mice compared
with KrasG12D mice (Figures 3L–3O).
Similar results were observed in reciprocal bone marrow
chimeras. Bone marrow from wild-type (WT) (Il-6+/+) or Il-6-/-
mice was introduced into irradiated KrasG12D, according to the
schedule in Figure S2B. As shown in Figure S2C, reconstitution
of KrasG12D mice with IL-6-competent (Il-6+/+) bone marrow
(BM-Il-6+/+KrasG12D) induced PanIN progression, as evidenced
by PanIN-3 lesions throughout the entire pancreas in three of
the four transplanted mice. None of the BM-Il-6-/-KrasG12D
mice developed high-grade PanIN lesions (Figures S2D–S2G).
Accordingly, Stat3 phosphorylation in PanIN lesions was attenu-
ated in BM-Il-6-/-KrasG12D mice (Figures S2H–S2I).
Collectively, these data suggest that myeloid cells use IL-6
transsignaling rather than classical IL-6 signaling to promote
PanIN progression. The downstream effector Stat3 appears to
be associated with the development of PanIN lesions.
Stat3 Constitutes a Central Node that Mediates PanIN
Progression and PDAC Development
Because Stat3 is considered the major protumorigenic effector
of IL-6, we determined the contribution of pancreatic Stat3 to
PanIN progression and PC development. By immunofluores-
cence, we observed early phosphorylation of Stat3 at tyrosine
residue 705 in the pancreas of 13-week-old KrasG12D mice
(Figures 4A–4C, white star) and in infiltrating macrophages
(Figures 4A–4C, white arrows). In parallel, the expression of
bona fide Stat3 target genes increased in the pancreas of these
mice (data not shown). The widespread phosphorylation of Stat3
in the pancreas clearly suggested paracrine/autocrine stimula-
tion rather than a cell-autonomous effect.
To examine the effect of Stat3 activation in the exocrine
pancreas during oncogenesis, we generated compound mutant
KrasG12Dmice that lackedphosphorylatableStat3Y705 specifically
in the exocrine pancreas andparts of the endocrine compartment
using the Ptf1a-creex1 mouse line (KrasG12D;Stat3Dpanc) (Algul
et al., 2007a; Nakhai et al. 2007; Sano et al., 1999).Stat3 inactiva-
tion had no effect on pancreatic development in adult mice, and
basal proliferation rate and apoptotic index were indistinguish-
able between Stat3Dpanc and Stat3F/F under steady-state condi-
tions (to be published elsewhere).
Inactivation of theStat3 pathwaywasconfirmedby IB analysis.
Whereas KrasG12D mice experienced strong Stat3 phosphoryla-
tion at tyrosine residue 705 at 9 and 13 weeks, Stat3-deficient
KrasG12D mice failed to express p-Stat3Y705. In contrast, Stat1
phosphorylation did not differ between genotypes (Figure 4D).
Consistent with the KrasG12D expression in both mouse lines,
total protein lysates from the pancreata of compound mutant
mice expressed increased levels of activated and GTP-bound
Ras (not significant between lines), concomitant with the induc-
tion of the downstream targets ERK1 and ERK2 (Figure 4E).
Notably, the typical macroscopic appearance (enlarged
pancreas and focally nodular parenchyma) of KrasG12D mice
was absent in KrasG12D;Stat3Dpanc mice 13 weeks postpartum
(p.p.); the KrasG12D;Stat3Dpanc pancreas was similar to that inCancer Cell 19, 456–469, April 12, 2011 ª2011 Elsevier Inc. 459
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Figure 3. IL-6 Transsignaling Promotes PanIN Progression
(A) Stimulation of isolated acinar cells derived from KrasG12D mice. Acinar cells were incubated with CCK (100 nM), IL-6 (150 ng/ml), or Hyper-IL-6 (H-IL-6
150 ng/ml) or were untreated. Lysates were analyzed for p-Stat3Y705. Stat3 served as the positive control.
(B–J) Representative H&E-stained pancreatic sections from 18week oldKrasG12D (B and C),KrasG12D;Il-6-/- (E and F), andKrasG12D;sgp130tgmice (H and I). Black
star indicates PanIN-3 lesions; black arrows indicate PanIN-1 lesions. Immunohistochemical analysis of MUC5 in the pancreas of 18 week old KrasG12D
(D) KrasG12D;Il-6-/- (G) and KrasG12D;sgp130tg (J) mice.
(K) Number of PanINs was counted per 200x field. Means ± SD (n = 6), *p < 0.05 and **p < 0.005; ND, (not detectable).
(L–N) Immunohistochemical detection of p-Stat3Y705 in 18 week old mice of the indicated genotypes.
(O) Immunoblot analysis of p-Stat3Y705 and Stat3 in lysates from KrasG12D, KrasG12D;Il-6-/-, and KrasG12D;sgp130tg mice.
Scale bars equal 500 mM (B, E, H, D, G, and J) and 50 mM (C, F, I, L, M, and N). See also Figure S2.
Cancer Cell
IL-6 Transsignaling and Stat3 in Pancreatic CancerLSL-KrasG12D mice (Figure 4F). Histologically, KrasG12D mice
developed progressive PanIN lesions (Figures 4G–4L, black
arrow), which was not observed in KrasG12D;Stat3Dpanc mice
(Figures 4M–4R). Only rare reactive ducts (Figure 4P, white
arrow) and low-grade PanIN lesions (PanIN-1) (Figure 4R, black
arrow) were detectable in 13 and 18 week old mice, suggesting
that Stat3 inactivation in the pancreas prevents PanIN progres-
sion but not its initiation (Figure 4S).
To determine whether Stat3 inactivation influences PDAC
development, we followed two cohorts, 20 KrasG12D and 41
KrasG12D;Stat3Dpanc mice, for nearly two years (Table 1; Table
S1). The mice were sacrificed when they became moribund,
particularly if they presented with weight loss, ascites, jaundice,
a palpable abdominal mass, or any other compromising disease.
Only 24.5% (10/41) of theKrasG12D;Stat3Dpancmice developed
PC, and 55% (11/20) of KrasG12D mice succumbed to PC (Fig-
ure 4T). Tumor proliferation index was significantly lower in
Stat3-deficient KrasG12D mice compared with KrasG12D animals
(Figure 4U). Tumors from KrasG12D;Stat3Dpanc mice did not
express nuclear Stat3 in the primary cancer or its metastasis460 Cancer Cell 19, 456–469, April 12, 2011 ª2011 Elsevier Inc.(Figures S3A and S3B); in adjacent tissues, p-Stat3Y705 expres-
sion was restricted to inflammatory cells (Figure S3C). Accord-
ingly, cell lines from KrasG12D;Stat3Dpanc mice did not respond
to IL-6 (Figure S3D) because they failed to phosphorylate Stat3.
Consequently, proliferation was delayed after incubation with
various concentrations of FCS (Figure S3E) and IL-6 (Figures
S3F). Similar results were obtained when these cell lines were
incubated with Hyper-IL-6 (data not shown). These cell lines ex-
pressed a slightly smaller version of Stat3, termed as Stat3Dpanc.
Collectively, our data suggest that epithelial Stat3 is required
for the transduction of tumor-promoting signals of IL-6, particu-
larly during the progression of PanIN to PDAC, but not in the initi-
ation of PanIN.
Stat3 Regulates Cell-Autnomous Effects during
Pancreatic Oncogenesis in KrasG12D Mice
Apoptosis is a rare event in early and late PanIN lesions, while
proliferation is detectable and predominant throughout progres-
sion (Luttges et al., 2003). Thus, we analyzed these aspects to
determine the molecular mechanisms by which Stat3 confers
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Figure 4. Stat3 Is Essential for PanIN Progression
(A–C) Immunofluorescence analysis of p-Stat3Y705 and F4/80 in pancreata of 13 week old LSL-KrasG12D mice. White arrows indicate F4/80-positive macro-
phages, white star acini (see magnification).
(D) Immunoblot analysis of p-Stat3Y705 and p-Stat1Y701 in lysates from KrasG12D and KrasG12D;Stat3Dpanc mice.
(E) Immunoprecipitation of activated Ras with Raf-1 RBD agarose. Immunoblot analysis with anti-Ras and p-ERK1/2 and ERK1/2. Panc-1 lysates were positive
controls.
(F) Macroscopic view of pancreas from LSL-KrasG12D, KrasG12D, and KrasG12D;Stat3Dpanc mice.
(G–R) Representative H&E-stained sections from mice of the indicated genotypes. Black arrows indicate PanIN lesions; white arrow is reactive ducts.
(S) Number of PanINs was counted per 200x field. Means ± SD (n = 6), **p < 0.005, ***p < 0.0005. ND, not detectable.
(T) Determination of tumor incidence in both mouse cohorts, *p < 0.05.
(U) Proliferation index was measured in BrdU-stained PC sections from KrasG12D (n = 9) and KrasG12D;Stat3Dpanc mice. Means ± SD (n = 5), ***p < 0.0005. Scale
bars equal 50 mM (A, B, C, H, J, L, N, P, and R) and 500 mM (G, I, K, M, O, and Q). See also Figure S3.
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specific inactivation of the Stat3 cascade renders acinar/ductal
cells more susceptible to apoptosis, we measured caspase-3
cleavage in 13 week old mice by IHC.
Many acinar and ductal cells in the pancreas of KrasG12D;
Stat3Dpanc mice were positive for cleaved caspase-3 (Figure 5A,
magnified box), which was absent in KrasG12D mice (Figure 5B,
magnified box); this finding was confirmed by quantification (Fig-
ure 5C) and immunoblot analysis (data not shown). By immuno-
blot, Bcl-XL, Survivin, and Mcl-1 were upregulated in Kras
G12D
mice but absent in KrasG12D;Stat3Dpanc mice, consistent withfindings that bcl-x, survivin, and mcl-1 are transcriptionally
induced by Stat3 (Figure S4A) (Yu et al., 2009).
To determine whether Stat3 regulates proliferation in the
pancreas of KrasG12D mice, we injected mice with 5-bromo-2-
deoxyuridine (BrdU), which incorporates into newly synthesized
DNA, and sacrificed the animals two hours later. By anti-BrdU
staining, we observed the time-dependent incorporation of
BrdU into acinar and ductal cells (data not shown), but mice
that were deficient for phosphorylable Stat3Y705 expressed
fewer BrdU-positive cells in the pancreas, even after 13 weeks
of age (Figure 5D). Consistent with this result, proliferating cellCancer Cell 19, 456–469, April 12, 2011 ª2011 Elsevier Inc. 461
Table 1. Clinical Spectrum of Diseases in KrasG12D;Stat3Dpanc Mice
ID Age (days) PDAC Histology Liver Lung Diaphragm Ascites Other
302 369 Y G YM YM N N BO, pLN
303 240 N N N N N A
317 480 N N N N N A
320 426 N N N N N A
321 484 Y U YM N N N P
322 537 N N N N N A
352 445 Y U YM YM YM N pLN
362 329 Y G YM YM N N BO
365 381 Y G N N N Y
370 314 N N N N N SD
371 213 N N N N N
407 361 Y U N N N N P
408 396 N N N N N A
419 445 Y U N N N N
2163 413 Y U YM N N Y pLN, BO
2206 113 N N N N N SD
2755 331 N N N N N A, SD
2756 239 N N N N N
2827 213 N N N N N P
2865 489 N N N N N A
2950 573 N N N N N A
2951 438 N N N N N A
2959 306 N N N N N A
2969 386 N N N N N A, SD
2992 136 Y G N N N N
3038 707 N N N N N A, SD
3045 447 N N N N N P
3050 699 N N N N N A
3098 166 N N N N N A
3103 426 N N N N N A
3140 683 N N N N N A
3141 418 N N N N N A
3142 510 N N N N N A
3144 320 N N N N N A, P
5101 609 N N N N N
5105 609 N N N N N
5110 277 N N N N N A, SD
5185 191 Y G N N N N SD
5277 341 N N N N N A, SD
5311 233 N N N N N A
5530 452 N N N N N A
Totals 10/41 5/41 3/41 1/41 2/41
pLN, peripancreatic lymph node; M, metastasis; pC, pancreatic cyst; U, undifferentiated; G, glandular; A, atrophy; SD, skin disease; BO, biliary
obstruction; P, paralysis.
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IL-6 Transsignaling and Stat3 in Pancreatic Cancernuclear antigen (PCNA) expression was generally higher in
KrasG12D mice (Figure 5E).
Next, we identified proteins that were expressed during prolif-
eration by generating pancreatic protein lysates from 9 and
13 week old KrasG12D and KrasG12D;Stat3Dpanc mice and per-462 Cancer Cell 19, 456–469, April 12, 2011 ª2011 Elsevier Inc.forming immunoblot analysis of cell cycle regulators. The time-
dependent induction of Cyclin D1 and c-myc was attenuated in
KrasG12D;Stat3Dpanc mice, suggesting that Stat3Y705 phosphory-
lation regulates proliferation during KrasG12D-driven PanIN
progression (Figure 5E).
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Figure 5. Stat3 Regulates Apoptosis and Influences Cell Cycle Progression during PanIN Progression
(A and B) Immunohistochemical analysis of cleaved caspase-3 in pancreata of KrasG12D and KrasG12D;Stat3Dpanc mice.
(C) Apoptosis (cleaved caspase-3) index in pancreas of KrasG12D (n = 6mice, 20 fields per mouse) and KrasG12D;Stat3Dpancmice (n = 7mice, 20 fields per mouse).
Means ± SD, ***p < 0.0005.
(D) BrdU proliferation index of pancreas in KrasG12D (n = 6 mice, 20 fields per mouse) and KrasG12D;Stat3Dpancmice (n = 7 mice, 20 fields per mouse). Means ± SD
(nR 5), **p < 0.005.
(E) Immunoblot analysis of the indicated proteins in lysates from both genotypes. Scale bars equal 200 mM.
See also Figure S4.
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IL-6 Transsignaling and Stat3 in Pancreatic CancerFurther, Stat3 seems to be involved in concomitant inflamma-
tion in the pancreas, as the accumulation of F4/80-positive
macrophages declined in Stat3-proficient mice (Figures S4B
and S4C). In addition, the Stat3-dependent and proinflammatory
enzyme Cox-2 was not expressed in KrasG12D;Stat3Dpanc mice
compared with KrasG12D animals (Figure S4D). Cox-2 was
detectable in acinar cells and in ductal lesions (Figures S4E
and S4F).
Based on our data, we conclude that Stat3 activation regu-
lates KrasG12D-dependent effects on apoptosis, proliferation,
and inflammation.
Homozygous Deletion of Socs3 Accelerates PanIN
Progression and Promotes PDAC Development
Although Stat3 regulates PanIN progression, it is unknown
whether Stat3 alone is sufficient to mediate these effects.
Stat3 activation is tightly regulated by the endogenous feedback
inhibitor Socs3, which inhibits Stat3 signaling by binding to
gp130.
KrasG12D mice expressed high levels of Socs3 mRNA (Fig-
ure 6A). Socs3 was detectable in acinar cells (Figure 6B, blackarrows) and PanIN lesions (Figure 6B, white arrows) of KrasG12D
mice.
To induce early and prolonged activation of p-Stat3Y705 in the
pancreas of these mice, we generated a mutant mouse line that
lacked Socs3 specifically in the pancreas (Nakaya et al., 2009).
Hetero- or homozygous deletion of Socs3 did not affect pancre-
atic morphology or cellular homeostasis (data not shown).
Homozygous deletion of Socs3 in KrasG12D mice (KrasG12D;
Socs3Dpanc), however, induced early and high phosphorylation
levels of Stat3Y705 in the pancreas as early as four weeks of
age (Figure 6C).
At this age, KrasG12D;Socs3Dpanc mice developed large areas
of reactive ducts (Figure 6K) and low- (Figure 6H) and high-grade
(Figure 6E) PanINs throughout the pancreas (Figure 6D). The
nuclei of ductal lesions and acinar cells were positive for phos-
phorylated Stat3Y705 (Figures 6F–6L) and Cyclin D1 (Figures
6G–6M). By quantification of ductal lesions, we observed rapid
progression of PanINs in these mice (Figure 6N).
To determine whether the deletion of Socs3 and the subse-
quent early and robust activation of Stat3 influences PDAC
development, we monitored 41 KrasG12D;Socs3Dpanc mice forCancer Cell 19, 456–469, April 12, 2011 ª2011 Elsevier Inc. 463
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Figure 7. Evidence of IL-6/Stat3 Cascade in Human PDAC
(A and B) Analysis of IL-6 and soluble IL-6R in patients with PDAC.
(C–J) H&E staining and detection of p-Stat3Y705, CD3, and CD68 in human PDAC (B–E) and in adjacent nonmalignant tissue (F–I). White arrows indicate infiltrating
cells.
(K–N) Immunofluorescence analysis of human specimens. Nuclei were visualized with DAPI. Anti-IL-6 and anti-CD68 were used to label IL-6 and macrophages.
Signals were merged to identify the site of IL-6 production.
(O) Scheme of the central role of Stat3 in PanIN progression and PDAC development. Scale bars equal 50 mM.
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IL-6 Transsignaling and Stat3 in Pancreatic Cancernearly one year (Table S2). The combination of activated
KrasG12D and Socs3 deficiency led to significant decreases in
body and pancreatic weight (data not shown). As shown in Fig-
ure 6O, these mice reached terminal morbidity between 6 and
31 weeks of age and had a median survival of 111 days
(p < 0.0001 for KrasG12D;Socs3Dpanc colony compared with
KrasG12D cohort). Within the observation period, 37.5% (12/32)
of KrasG12D;Socs3Dpanc mice developed pancreatic cancer
(Table S2). These ductal adenocarcinomas (Figure 6P) were
positive for CK-19 (Figure 6Q) and p-Stat3Y705 (Figure 6R). Phos-
phorylated Stat3Y705 was restricted primarily to the nuclei of
cancer cells (Figure 6S). Tumor latency in these mice was lower
compared with KrasG12D mice (93 vs 428 days, Figure 6T).
Collectively, these results suggest that levels of Stat3 phos-
phorylation determine the progression of PanIN lesions to
pancreatic cancer.Figure 6. Homozygous Deletion of Socs3 Enhances Stat3 Activation, P
(A) Relative expression of Socs3 mRNA in pancreas from 9 week old KrasG12D m
(B) Immunohistochemical localization of Socs3 in the pancreas of 9 week old Kra
within PanIN lesions.
(C) Immunoblot analysis of p-Stat3Y705 and b-actin in lysates from 4 week old Kr
(D–M) Representative H&E staining and detection of CK-19, p-Stat3Y705, and Cy
(N) Number of PanINs was counted per 200x field. Means ± SD (n = 5), **p < 0.0
(O) Kaplan-Meier curves show a median survival in KrasG12D;Socs3Dpancmice of 1
test, for pairwise combination).
(P–S) Ductal adenocarcinoma (P) from an approximately 2 month old mouse (ID 5
p-Stat3Y705 (R, see magnification in S).
(T) Tumor latency in KrasG12D (n = 11) and KrasG12D;Socs3Dpanc (n = 12) cohorts.
Scale bars equal 500 mM (D) and 50 mM (B, E–M, and P–R). See also Table S2.Evidence for the IL-6/Stat3 Cascade in Human PDAC
To determine the relevance of the observed link between
myeloid IL-6 and p-Stat3Y705 in PDAC, we measured IL-6 and
soluble IL-6-receptor (sIL-6R) levels in patients with PDAC.
Serum IL-6 levels in 39 patients were significantly higher than
in healthy control groups (Figure 7A), and sIL-6R levels did not
differ (Figure 7B).
Based on the the significantly high systemic levels of IL-6 and
the presence of sIL-6R in patients, we examined whether the
IL-6/Stat3 cascade was detectable locally in human specimens
(Figures 7C and 7D) by performing the IHC of p-Stat3Y705 and
IL-6 in human specimens of PDAC. Notably, Stat3 was activated
in PDAC (Figure 7E) and in the acinar cells or early PanIN lesions
in tumor-adjacent tissues, similar to the observations in our
mouse models (Figure 7F). Most infiltrating cells were macro-
phages by anti-CD68 staining (Figure 7E), and CD3-positiveromotes PDAC Development, and Reduces Survival in KrasG12D Mice
ice. Means ± SD (nR 5), **p < 0.005.
sG12D mice. Black arrows indicate positivity within acini, white arrows positivity
asG12D and KrasG12D;Socs3Dpanc mice.
clin D1 in pancreas from 4 week old KrasG12D;Socs3Dpanc mice.
05, and ***p < 0.0005. ND, (not detectable).
11 days, significantly less (459 days) than KrasG12D mice (p < 0.0001, log-rank
250), demonstrating CK-19 (Q) expression and abundant nuclear localization of
Means ± SD, ***p < 0.0005.
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IL-6 Transsignaling and Stat3 in Pancreatic Cancerlymphocytes were scattered around cancer cell clusters and
preneoplastic lesions (Figures 7G and 7H). In tumor-adjacent
tissues, macrophages were observed between nontransformed
acini (Figure 7I). By immunofluorescence, macrophages were
determined to be the principal source of IL-6 (Figures 7K–7N).
Collectively, these data suggest that the basis for classical
IL-6 and IL-6 transsignaling, linking myeloid IL-6 to p-Stat3Y705
in preneoplastic or neoplastic cells, exists in human PDAC and
potentially define a mechanism of pancreatic oncogenesis.
DISCUSSION
Aberrant activation of Stat3 in the absence of Jak2 mutations is
a recurring theme in human PDAC; however, its implication in
pancreatic oncogenesis in vivo has remained undetermined
(Glienke et al., 2010; Hutzen et al., 2009; Lin et al., 2010b; Scholz
et al., 2003). Using genetic and pharmacological tools, we iden-
tified important functions of IL-6 and Stat3 and their implications
for multiple aspects of pancreatic oncogenesis.
Also, we detailed a signaling network between stromal and
preneoplastic pancreatic cells and identified Stat3 as the critical
node in this interplay. Our study provides evidence that myeloid
cells release IL-6 to induce Stat3 activation in the pancreas via
IL-6 transsignaling, thus potentiating a feed-forward response
in the tumor microenvironment to promote PanIN progression
and, ultimately, PDAC development in vivo. Genetic inactivation
of classical IL-6 signaling, IL-6 transsignaling, and the Stat3
effector pathway impaired PanIN progression and PDAC devel-
opment (Figure 7O).
By identifying the underlying mechanisms, we have explained
the implications of IL-6 and myeloid cells in human PDACmech-
anistically. Many studies have observed a robust and consistent
assocation of IL-6 with patient outcomes (Ebrahimi et al., 2004;
Talar-Wojnarowska et al., 2009), and a specific polymorphism
of IL-6 has been reported to be overrepresented in such patients
(Talar-Wojnarowska et al., 2009). The density of inflammatory
cells in pancreatic carcinoma, especially of macrophages, has
predictive value for patient prognoses (Kurahara et al., 2009).
In this study, we found that pancreatic myeloid cells mediate
tumor promotion substantially by releasing IL-6 into the stroma.
Consistent with this observation, enhanced pancreatic inflam-
mation in KrasG12D mice through repetitive application of the
hormone cerulein accelerates PanIN progression and PDAC
development, underscoring the significance of inflammatory
cells in these settings (Guerra et al., 2007). Because cerulein fails
to induce phosphorylation of Stat3 in acinar cells derived from
KrasG12D mice in vitro, we assume that inflammatory cells
release IL-6 to induce p-Stat3 in the pancreas, thus promoting
oncogenesis in this inflammation-associated model of PDAC.
The paracrine effects of IL-6, however, are not restricted to
preneoplastic and cancer cells in the pancreas. We observed
Stat3 activation in infiltrating macrophages and normal hepato-
cytes that surrounded metastatic lesions, suggesting a general
effect of IL-6 on the various cells that constitute the micro-
environment; whether this activation in nontransformed cells
impacts oncogenesis or the formation of metastatic lesions is
unknown.
The IL-6/Stat3 cascade appears to be ubiquitous—not
restricted solely to the pancreas. In a model of inflammation-466 Cancer Cell 19, 456–469, April 12, 2011 ª2011 Elsevier Inc.associated colorectal carcinogenesis, for example, myeloid
IL-6 activates Stat3 to promote the formation of adenoma and
tumors (Bollrath et al., 2009; Grivennikov et al., 2009). Our data
do not exclude the involvement of other cytokines, because
transgenic overexpression of Il-1beta in the pancreas has been
shown to be sufficent to induce proliferation, robust desmopla-
sia, and rare acinar-ductal metaplasia (Marrache et al., 2008).
Notably, IL-1b failed to acitvate Stat3 in pancreatic cancer cells,
suggesting that other signaling pathways transmit its signals in
the pancreas.
Although the involvement of IL-6 in cancer-promoting inflam-
mation in various organs is well established, no study has
implicated IL-6 or IL-6 transsignaling in spontaneous tumor
formation. Using the KrasG12Dmodel in the pancreas, we defined
a central function for IL-6 during oncogenesis.
Two distinct processes control IL-6 responses in vivo. IL-6
signals are transmitted via gp130 through IL-6 engagement of
IL-6R or formation of a complex with soluble IL-6R (i.e., IL-6
transsignaling). Because IL-6R is sparsely expressed, IL-6 trans-
signaling increases the number of potential IL-6 target cells
(Rose-John et al., 2006). Nontransformed acinar cells that
express oncogenic KrasG12D require IL-6 transsignaling to
induce robust phosphorylation of Stat3. IL-6 itself is predomi-
nantly secreted by inflammatory cells, most likely in an NF-kB-
dependent manner. Similarily, recruitment of these cells to the
pancreas also involves induction of NF-kB, potentially as
a consequence of KrasG12D dependent activation (Finco et al.,
1997). Beyond its capacity to secret IL-6, immune cells have
also been shown to participate in the process of IL-6R shedding
(Chalaris et al., 2007), a process that also involves the metallo-
proteinases ADAM17 (a desintegrin and metalloproteinase),
and to a lesser extent ADAM10 (Matthews et al., 2003). In addi-
tion to its function as an important regulator of proinflammatory
chemokines and cytokines, NF-kBmight therefore be implicated
in establishing IL-6 transsginaling during pancreatic oncogen-
esis (Algul et al., 2007c; Guerra et al., 2007). Whether the
metallproteinases ADAM17 and ADAM10 has a role to play,
and what role it plays, during pancreatic oncogenesis remains
to be elucidated in further studies. Using genetic tools, we herein
found that IL-6 transsignaling, not classical IL-6 signaling, entails
Stat3 activation to promote PanIN progression in vivo. Thereby,
our data extend previous findings implicating immune cells to
include myeloid-derived suppressor cells, tumor-associated
macrophages, and Treg in PDAC development (Clark et al.,
2007).
The major protumorigenic IL-6 effector is Stat3, the ablation or
prolonged activation in the pancreas of which influences PanIN
progression but not PanIN initiation. Stat3 has been implicated
in apoptosis and cell cycle progression during oncogenic
(KrasG12D) stress. We identified Stat3 activation as the chief
mediator of programmed cell death. Stat3 upregulated the anti-
apoptotic proteins Bcl-XL, Mcl-1, and Survivin, which were
recently demonstrated to be Stat3 target genes (Yu et al.,
2009). Their activity during apoptosis in pancreatic cancer has
also been observed.
Inhibition of Stat3 in human pancreatic cancer cells facilitates
apoptosis and inhibits chemoresistance (Lin et al. 2010a).
Persistent Stat3 activation during PanIN progression also medi-
ates the proliferation of preneoplastic lesions in the pancreas.
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IL-6 Transsignaling and Stat3 in Pancreatic CancerSimilarily, deletion of IKK in hepatocytes effects chronic Stat3
activation, inducing proliferation and promoting hepatocellular
carcinoma on exposure to diethylnitrosamine (He et al., 2010).
Consistent with this observation, Stat3 inactivation mitigates
the incorporation of BrdU in the pancreas, paralleled by impaired
induction of Cyclin D1 (Masuda et al., 2002) and c-myc (Barre
et al., 2005), which are regulated by nuclear Stat3 and overex-
pressed in human specimens of PDAC (Kawesha et al., 2000).
These factors are central in driving cancer cells from G0/G1 to
S phase, propelling cell cycle progression. Similarly, isolated
pancreatic cancer cell lines from Stat3-deficient KrasG12D mice
proliferated less in response to FCS, IL-6, and Hyper-IL-6.
Intracellular regulation of Stat3 activation is tightly controlled
by the concomitant expression of its endogenous inhibitor,
Socs3 (Yu et al., 2009). In KrasG12D mice, we noted high pancre-
atic levels of Socs3, suggesting that the activation and inhibition
of Stat3 are balanced during PanIN progression. Deleting both
alleles of Socs3 in KrasG12D tipped this balance toward robust
phosphorylation of Stat3, which accelerated the progression of
PanIN lesions and the development of PC. Survival and tumor
latency were curtailed in Socs3-deficient KrasG12D mice. Thus,
we propose that the Stat3/Socs3 pathway assumes a central
role during pancreatic oncogenesis.
The most notable observations pertained to tumor cells from
PDAC in KrasG12D mice. All cancer cell lines that we examined
failed to exhibit constitutive phosphorlyation of Stat3, which
formed the basis for our hypothesis that Stat3 activation during
pancreatic oncogenesis depends on the microenvironment.
These findings contrast other studies that have observed consti-
tutive phosphorylation of Stat3 in nearly all human pancreatic
cancer cell lines (Glienke et al. 2010; Greten et al., 2002; Hutzen
et al., 2009; Kim et al. 2010; Lin et al. 2010a; Scholz et al., 2003;
Trevino et al., 2006).
One explanation for this discrepancy proposes that additional
mutations in p53 in human cancer cell lines mediate constitutive
phosphorylation of Stat3, as seen in other tumor cells (Lin et al.,
2002). Wild-type p53 regulates Stat3 phosphorylation in ovarian
cancer cell lines (Caov-3 and MDAH2774) by controlling Jak2
through p53-dependent upregulation of protein tyrosine phos-
phatase 1-B (PTP-1B), which inactivates Jak2 (Reid et al.,
2004). The balance between PTP-1B and Jak2 is likely to be dys-
regulated in human pancreatic cancer cell lines, because nearly
all established human PDAC cell lines harbour p53mutations (Si-
pos et al., 2003). In contrast, such mutations were absent in the
cell lines that were derived from KrasG12Dmice (data not shown).
We have identified an important mechanism that determines
the progression and development of PanIN to PDAC.
KrasG12D-induced pancreatic oncogenesis depends on the
microenvironment, wherein myeloid cells in the pancreas accel-
erate PanIN progression and PDAC development by releasing
IL-6. In examining the routes of IL-6 dependent activation of
Stat3, we have demonstrated a relevant function of IL-6 transsig-
nalling in pancreatic oncogenesis. Through IL-6 transsignaling
and Stat3, IL-6 promotes tumor development in the pancreas.
Genetic manipulation of IL-6 transsignaling and Stat3 activation
impairs PanIN formation and significantly impedes PDAC devel-
opment. Using patient data and human PDAC specimens, we
have demonstrated that this crosslink also exists in the human
disease.EXPERIMENTAL PROCEDURES
Mice
The LSL-KrasG12D knockin (Jackson et al., 2001), Ptf1a-creex1 (Nakhai et al.,
2007),Stat3F/F (Sano et al., 1999), sgp130tg (Rabe et al., 2008), andSocs3F/F (Na-
kaya et al., 2009) strains were interbred to obtain compound mutant
LSL-KrasG12D;Stat3F/F;Ptf1a-creex1 (termed KrasG12D;Stat3Dpanc), LSL-
KrasG12D;Ptf1a-creex1;sgp130tg (termed KrasG12D;sgp130tg), or LSL-KrasG12D;
Socs3D/D;Ptf1a-creex1 (termed KrasG12D;Socs3Dpanc) mice. LSL-KrasG12D (the
negative control) and mutant LSL-KrasG12D;Ptf1a-creex1 (termed KrasG12D, the
positive control) mice were used as control animals.
Il-6-/- (C57BL/6 background) mice were obtained from The Jackson Labora-
tory, Maine. LSL-KrasG12D knockin and Il-6-/- mice were interbred to generate
LSL-KrasG12D;Il6-/-;Ptf1a-creex1 mice (termed KrasG12D;Il6-/-). All procedures
conformed to the regulatory standards and were approved by the Regierung
von Oberbayern.
Human Serum IL-6 Measurements
Serum samples were obtained from 38 patients with histologically or cytolog-
ically confirmed PDCA from whom pretreatment serum samples were avail-
able. The analysis group consisted of 15 females (median age 67 years, range
41–81 years) and 23 males (median age 68 years, range 50–80 years). Whole
blood was collected prior to administration of chemotherapy. Serological anal-
ysis was performed at the Institute for Clinical Chemistry, Technical University,
Munich. Control sera were obtained from healthy probands. The Local Ethics
Committee approved the analysis, and written informed consent was obtained
from all patients and controls.
Quantification of Proliferation, Apoptosis, and Inflammation
Mice were injected intraperitoneally with 50 mg/kg BrdU (Sigma) 2 hr prior to
sacrifice, and paraffin sections were stained with anti-BrdU. Apoptosis was
measured by immunohistochemistry of cleaved caspase-3. Inflammation
was assessed using macrophage markers (F4/80). For each analysis, positive
cells were scored in the pancreata from several animals of each genotype.
Flow Cytometry
Pancreata were injected with 1.2 mg/ml collagenase P (Roche) and minced.
Single-cell suspensions of pancreatic cells were immunolabeled with fluoro-
chrome-conjugated antibodies in PBS that was supplemented with 2% heat-
inactivated FBS (Gibco-Invitrogen) and 5 mM EDTA (Sigma). All antibodies
were purchased from eBioscience: eFluor 450-conjugated anti-CD45,
fluorescein isothiocyanate-conjugated anit-CD19, PE-conjugated anti-F4/80,
allophycocyanin-conjugated anti-CD11c, APC-eFluor 780-conjugated anti-
CD11b, and Alexa Fluor 700-conjugated anti-CD3. Cells were stainedwith pro-
pidium iodide (BDBiosciences) to assess viability. Flowcytometry analysiswas
performed on a Gallios flow cytometer (Beckman Coulter) after gating and
excluding dead cells. Data were analyzed using FlowJo software.
Statistical Analyses
Data are presented as averages ± standard deviaions (SD) and were analyzed
by built-in t test usingMicrosoft Excel. p < 0.05 was considered significant. For
the overall survival analysis, Kaplan-Meier curves were analyzed by log rank
test. Tumor incidence was analyzed using Fisher’s exact test. In all cases,
we chose a group size that produced statistically unambiguous results.
SUPPLEMENTAL INFORMATION
Supplemental Information includes two table, four figures, and Supple-
mental Experimental Procedures and can be found with this article online
at doi:10.1016/j.ccr.2011.03.009.
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